0.58Open0.58Pre Close0 Volume64 Open Interest30.00Strike Price0.00Turnover145.34%IV66.65%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.58Extrinsic Value100Contract SizeAmericanOptions Type0.1392Delta0.0315Gamma43.18Leverage Ratio-0.0308Theta0.0015Rho6.01Eff Leverage0.0107Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet